The primary objective of the proposed pilot study is to determine the efficacy of pregabalin
in prolonging the time to onset of pain and reducing the severity of pain associated with
walking in patients with neurogenic claudication. Neurogenic claudication is defined as
movement induced leg pain, numbness, heaviness, or vague discomfort in part or all of one or
both legs provoked with walking and standing and relieved by sitting, squatting, or forward
flexion posturing. The secondary objective is to examine the functional benefit of pregabalin
with respect to improvement in duration and distance of walking.